USPSTF Releases Final Recommendation on Treatments for Reducing Breast Cancer Risk

Sep 4, 2019 – Risk-reducing therapies, such as tamoxifen, raloxifene, or aromatase inhibitors, should be administered to women who are at an increased risk for breast cancer and at a low risk for adverse events (AEs) associated with these medications, according to an updated recommendation statement released by the United States Preventive Services Task Force (USPSTF). In addition to this positive category B recommendation, the USPSTF also issued a category D … (leggi tutto)